# Bradycardia â€“ RRT Protocol with Virtua Voorhees Addenda

**Primary Guideline:** American Heart Association (AHA) Advanced Cardiovascular Life Support (ACLS) 2020 Guidelines (Current through 2025)
**Official Source:** https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/adult-advanced-cardiovascular-life-support
**Supporting Guidelines:**
- 2018 AHA/ACC/HRS Guideline on the Evaluation and Management of Patients with Bradycardia
- 2025 ACLS Algorithm Updates

## ENHANCED MERMAID FLOWCHART ALGORITHM

~~~mermaid
graph TD
    A["Bradycardia Recognition<br/>HR <60 bpm + Symptoms"] --> B{"Patient<br/>Symptomatic?"}
    
    B -->|NO| C["Monitor & Observe<br/>Treat Underlying Causes"]
    B -->|YES| D["Initial Stabilization<br/>O2, IV, Monitor, 12-lead ECG"]
    
    D --> E{"Bradycardia<br/>Type?"}
    
    E -->|"Sinus Brady/1st Degree"| F["Atropine 1mg IV<br/>Repeat q3-5min (max 3mg)"]
    E -->|"2nd Degree Type II/3rd Degree"| G["Transcutaneous Pacing<br/>Immediate Setup"]
    
    F --> H{"Adequate<br/>Response?"}
    
    H -->|YES| I["Continue Monitoring<br/>Treat Underlying Cause"]
    H -->|NO| J["Chronotropic Support<br/>Dopamine 5-20 mcg/kg/min"]
    
    J --> K["Transcutaneous Pacing<br/>If Not Already Done"]
    G --> K
    
    K --> L{"Pacing<br/>Effective?"}
    
    L -->|YES| M["Optimize Settings<br/>Provide Sedation"]
    L -->|NO| N["Transvenous Pacing<br/>Cardiology Consult"]
    
    M --> O["Permanent Pacemaker<br/>Evaluation"]
    N --> O
    
    O --> P["Disposition<br/>ICU/Telemetry"]
    C --> P
    I --> P
    
    style A fill:#ffcccc
    style D fill:#ffe6cc
    style F fill:#fff2cc
    style G fill:#ccffcc
    style K fill:#e6ccff
    style P fill:#ccffee
~~~

## STREAMLINED DYNAMIC CARD SYSTEM

### Card 0 â€“ Bradycardia Recognition & Assessment (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ BRADYCARDIA RRT ACTIVATION            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Recognition criteria:                â”‚
â”‚ â€¢ Heart rate <60 bpm (typically <50)   â”‚
â”‚ â€¢ Associated symptoms present           â”‚
â”‚ â€¢ Hemodynamic compromise               â”‚
â”‚                                         â”‚
â”‚ ğŸ©º Immediate assessment:                â”‚
â”‚ â€¢ Mental status changes                â”‚
â”‚ â€¢ Hypotension/signs of shock           â”‚
â”‚ â€¢ Ischemic chest discomfort            â”‚
â”‚ â€¢ Acute heart failure symptoms         â”‚
â”‚ â€¢ Syncope or near-syncope              â”‚
â”‚                                         â”‚
â”‚ â±ï¸ Time of onset: Document precisely    â”‚
â”‚ Duration: Note progression pattern      â”‚
â”‚                                         â”‚
â”‚ â“ Patient symptomatic?                 â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Immediate intervention        â”‚
â”‚ ğŸ”˜ NO â†’ Monitor and observe            â”‚
â”‚                                         â”‚
â”‚ [Next: Based on Selection â–¶]            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1A â€“ Initial Stabilization (Node D â†’ E)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”§ INITIAL STABILIZATION PROTOCOL       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš€ Immediate actions:                   â”‚
â”‚ â€¢ High-flow oxygen if hypoxic          â”‚
â”‚ â€¢ Large-bore IV access Ã— 2             â”‚
â”‚ â€¢ Continuous cardiac monitoring        â”‚
â”‚ â€¢ 12-lead ECG (don't delay therapy)    â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Essential monitoring:                â”‚
â”‚ â€¢ Blood pressure, pulse oximetry       â”‚
â”‚ â€¢ Continuous ECG rhythm strip          â”‚
â”‚ â€¢ Consider arterial line if unstable   â”‚
â”‚                                         â”‚
â”‚ ğŸ” Investigate underlying causes:       â”‚
â”‚ â€¢ H's & T's assessment                 â”‚
â”‚ â€¢ Medication review                    â”‚
â”‚ â€¢ Electrolyte abnormalities           â”‚
â”‚                                         â”‚
â”‚ [Next: Bradycardia classification â–¶]   â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Recognition]              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1B â€“ Monitor & Observe (Node C - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ‘ï¸ ASYMPTOMATIC MONITORING              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ˆ Continuous surveillance:             â”‚
â”‚ â€¢ Telemetry monitoring                 â”‚
â”‚ â€¢ Vital signs q15min initially         â”‚
â”‚ â€¢ Watch for symptom development        â”‚
â”‚                                         â”‚
â”‚ ğŸ” Underlying cause evaluation:         â”‚
â”‚ â€¢ Medication-induced bradycardia       â”‚
â”‚ â€¢ Metabolic causes (hypothyroidism)    â”‚
â”‚ â€¢ Cardiac pathology assessment         â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Escalation triggers:                 â”‚
â”‚ â€¢ Development of symptoms              â”‚
â”‚ â€¢ HR <40 bpm                          â”‚
â”‚ â€¢ Pauses >3 seconds                    â”‚
â”‚                                         â”‚
â”‚ âœ… MONITORING PROTOCOL ACTIVE          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Recognition]              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ Bradycardia Classification (Node E)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ” BRADYCARDIA TYPE CLASSIFICATION      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š ECG analysis:                        â”‚
â”‚                                         â”‚
â”‚ ğŸ”µ Sinus bradycardia:                   â”‚
â”‚ â€¢ Normal P-QRS relationship            â”‚
â”‚ â€¢ PR interval normal/prolonged         â”‚
â”‚                                         â”‚
â”‚ ğŸŸ¡ First-degree AV block:               â”‚
â”‚ â€¢ PR interval >200ms, constant         â”‚
â”‚ â€¢ 1:1 P-QRS conduction                 â”‚
â”‚                                         â”‚
â”‚ ğŸŸ  Second-degree AV block:              â”‚
â”‚ â€¢ Type I (Wenckebach): Progressive PR  â”‚
â”‚ â€¢ Type II: Fixed PR, dropped QRS       â”‚
â”‚                                         â”‚
â”‚ ğŸ”´ Third-degree AV block:               â”‚
â”‚ â€¢ Complete AV dissociation             â”‚
â”‚ â€¢ Independent P and QRS rates          â”‚
â”‚                                         â”‚
â”‚ â“ Block type classification?           â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ SINUS/1ST DEGREE â†’ Atropine trial   â”‚
â”‚ ğŸ”˜ HIGH-GRADE BLOCK â†’ Immediate pacing â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3A â€“ Atropine Administration (Node F â†’ H)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’‰ ATROPINE ADMINISTRATION              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Updated 2025 dosing protocol:        â”‚
â”‚ â€¢ First dose: 1mg IV bolus              â”‚
â”‚ â€¢ Repeat: 1mg q3-5min                   â”‚
â”‚ â€¢ Maximum total: 3mg                    â”‚
â”‚                                         â”‚
â”‚ âš™ï¸ Mechanism of action:                  â”‚
â”‚ â€¢ Blocks vagal tone                     â”‚
â”‚ â€¢ Increases SA node firing rate         â”‚
â”‚ â€¢ Improves AV conduction                â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Limitations:                         â”‚
â”‚ â€¢ Less effective in 3rd degree block   â”‚
â”‚ â€¢ Ineffective in heart transplant      â”‚
â”‚ â€¢ May worsen Type II block (rare)       â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitor response:                     â”‚
â”‚ â€¢ HR improvement >60 bpm               â”‚
â”‚ â€¢ BP stabilization                     â”‚
â”‚ â€¢ Symptom resolution                   â”‚
â”‚                                         â”‚
â”‚ [Next: Response assessment â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Classification]           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3B â€“ Immediate Pacing Setup (Node G â†’ K)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âš¡ TRANSCUTANEOUS PACING SETUP          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš¨ High-risk indications:               â”‚
â”‚ â€¢ 2nd degree Type II AV block           â”‚
â”‚ â€¢ 3rd degree (complete) AV block        â”‚
â”‚ â€¢ Wide QRS escape rhythm                â”‚
â”‚ â€¢ Pauses >3 seconds                     â”‚
â”‚                                         â”‚
â”‚ ğŸ”§ Pacing pad placement:                â”‚
â”‚ â€¢ Anterior-posterior preferred         â”‚
â”‚ â€¢ Anterior-lateral alternative         â”‚
â”‚ â€¢ Clean/dry skin, clip hair if needed  â”‚
â”‚                                         â”‚
â”‚ âš™ï¸ Initial settings:                    â”‚
â”‚ â€¢ Rate: 80 ppm                         â”‚
â”‚ â€¢ Output: Start 30mA, increase by 10mA â”‚
â”‚ â€¢ Mode: Demand (synchronous)            â”‚
â”‚                                         â”‚
â”‚ [Next: Pacing effectiveness â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Classification]           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4A â€“ Chronotropic Support (Node J â†’ K)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’Š CHRONOTROPIC INFUSION THERAPY        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Updated 2025 dosing:                 â”‚
â”‚                                         â”‚
â”‚ ğŸ’‰ Dopamine (preferred):                â”‚
â”‚ â€¢ Dose: 5-20 mcg/kg/min IV infusion     â”‚
â”‚ â€¢ Start: 5 mcg/kg/min                   â”‚
â”‚ â€¢ Titrate to effect                     â”‚
â”‚                                         â”‚
â”‚ ğŸ’‰ Epinephrine (alternative):           â”‚
â”‚ â€¢ Dose: 2-10 mcg/min IV infusion        â”‚
â”‚ â€¢ Start: 2 mcg/min                      â”‚
â”‚ â€¢ Potent chronotropic effect           â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitoring parameters:               â”‚
â”‚ â€¢ HR response (target >60 bpm)         â”‚
â”‚ â€¢ BP improvement                       â”‚
â”‚ â€¢ Watch for arrhythmias                â”‚
â”‚                                         â”‚
â”‚ [Next: Transcutaneous pacing â–¶]        â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Atropine Response]        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5A â€“ Pacing Effectiveness (Node L)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“Š PACING EFFECTIVENESS ASSESSMENT      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âœ… Success indicators:                  â”‚
â”‚ â€¢ Electrical capture (pacing spikes    â”‚
â”‚   followed by QRS)                     â”‚
â”‚ â€¢ Mechanical capture (palpable pulse)  â”‚
â”‚ â€¢ Hemodynamic improvement              â”‚
â”‚                                         â”‚
â”‚ ğŸ”§ Troubleshooting failed pacing:      â”‚
â”‚ â€¢ Increase output (max 200mA)          â”‚
â”‚ â€¢ Reposition pads                      â”‚
â”‚ â€¢ Check connections                     â”‚
â”‚ â€¢ Consider lead displacement           â”‚
â”‚                                         â”‚
â”‚ ğŸ˜Œ Patient comfort measures:            â”‚
â”‚ â€¢ Sedation: Fentanyl 25-50mcg         â”‚
â”‚ â€¢ Anxiolysis: Midazolam 1-2mg          â”‚
â”‚ â€¢ Explain procedure to patient         â”‚
â”‚                                         â”‚
â”‚ â“ Pacing effective?                    â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Optimize settings & sedate    â”‚
â”‚ ğŸ”˜ NO â†’ Transvenous pacing needed     â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6A â€“ Pacing Optimization (Node M â†’ O)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”§ PACING OPTIMIZATION                  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âš™ï¸ Settings optimization:               â”‚
â”‚ â€¢ Threshold testing q4-6h               â”‚
â”‚ â€¢ Set output 2Ã— threshold              â”‚
â”‚ â€¢ Rate: 60-80 ppm (patient comfort)    â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Sedation protocol:                   â”‚
â”‚ â€¢ Assess pain level (0-10 scale)       â”‚
â”‚ â€¢ Titrate analgesics as needed         â”‚
â”‚ â€¢ Monitor respiratory status           â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Continuous monitoring:               â”‚
â”‚ â€¢ Capture confirmation                 â”‚
â”‚ â€¢ Hemodynamic stability                â”‚
â”‚ â€¢ Skin integrity at pad sites          â”‚
â”‚                                         â”‚
â”‚ [Next: Permanent pacemaker eval â–¶]     â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Pacing Effectiveness]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6B â€“ Transvenous Pacing (Node N â†’ O)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ TRANSVENOUS PACING CONSULTATION      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ Cardiology consultation:             â”‚
â”‚ â€¢ Transfer Center: 856-886-5111        â”‚
â”‚ â€¢ Electrophysiology if available       â”‚
â”‚ â€¢ Prepare for procedure                â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Indications for transvenous:         â”‚
â”‚ â€¢ Failed transcutaneous pacing         â”‚
â”‚ â€¢ High-grade AV blocks                 â”‚
â”‚ â€¢ Bridge to permanent device           â”‚
â”‚ â€¢ Extended pacing requirement          â”‚
â”‚                                         â”‚
â”‚ ğŸ› ï¸ Procedure preparation:               â”‚
â”‚ â€¢ Central venous access                â”‚
â”‚ â€¢ Fluoroscopy availability             â”‚
â”‚ â€¢ Pacing catheter system               â”‚
â”‚                                         â”‚
â”‚ [Next: Permanent pacemaker eval â–¶]     â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Pacing Effectiveness]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7 â€“ Permanent Pacemaker Evaluation (Node O â†’ P)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”‹ PERMANENT PACEMAKER EVALUATION       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“‹ Pacemaker indications:               â”‚
â”‚ â€¢ Symptomatic bradycardia              â”‚
â”‚ â€¢ High-grade AV blocks                 â”‚
â”‚ â€¢ Sinus node dysfunction               â”‚
â”‚ â€¢ Chronotropic incompetence            â”‚
â”‚                                         â”‚
â”‚ ğŸ¥ Evaluation process:                  â”‚
â”‚ â€¢ Electrophysiology consultation       â”‚
â”‚ â€¢ Echo to assess LV function           â”‚
â”‚ â€¢ Consider CRT if indicated            â”‚
â”‚                                         â”‚
â”‚ â±ï¸ Timing considerations:               â”‚
â”‚ â€¢ Urgent: Complete heart block         â”‚
â”‚ â€¢ Semi-urgent: Type II AV block        â”‚
â”‚ â€¢ Elective: Symptomatic sinus brady    â”‚
â”‚                                         â”‚
â”‚ ğŸ“š Patient education:                   â”‚
â”‚ â€¢ Device function explanation          â”‚
â”‚ â€¢ Activity restrictions                â”‚
â”‚ â€¢ Follow-up requirements               â”‚
â”‚                                         â”‚
â”‚ [Next: Disposition planning â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Pacing Management]        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 8 â€“ Disposition Planning (Node P - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ DISPOSITION & FOLLOW-UP              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ Disposition options:                 â”‚
â”‚                                         â”‚
â”‚ ğŸ”´ ICU admission:                       â”‚
â”‚ â€¢ Unstable bradycardia                 â”‚
â”‚ â€¢ Active pacing requirements           â”‚
â”‚ â€¢ Hemodynamic instability              â”‚
â”‚                                         â”‚
â”‚ ğŸŸ¡ Telemetry unit:                      â”‚
â”‚ â€¢ Stable bradycardia                   â”‚
â”‚ â€¢ Pacemaker evaluation pending         â”‚
â”‚ â€¢ Medication titration needed          â”‚
â”‚                                         â”‚
â”‚ ğŸŸ¢ Medical floor:                       â”‚
â”‚ â€¢ Asymptomatic bradycardia             â”‚
â”‚ â€¢ Stable after intervention            â”‚
â”‚ â€¢ Low-risk rhythms                     â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Follow-up coordination:              â”‚
â”‚ â€¢ Cardiology: 1-2 weeks                â”‚
â”‚ â€¢ Primary care: 1 week                 â”‚
â”‚ â€¢ Device clinic if pacemaker           â”‚
â”‚                                         â”‚
â”‚ âœ… DISPOSITION PROTOCOL COMPLETE       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Pacemaker Evaluation]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## VIRTUA VOORHEES BRADYCARDIA ADDENDA

### **Enhanced RRT Response:**
- **Rapid Response Team:** Immediate bedside assessment within 15 minutes
- **Equipment Availability:** Transcutaneous pacing pads on all RRT carts
- **Pharmacy Support:** Pre-mixed atropine and dopamine infusions available
- **Quality Metrics:** Door-to-atropine time, pacing success rates, patient outcomes

### **Updated 2025 ACLS Guidelines Integration:**
**Atropine Dosing Changes:**
- **First dose:** Increased from 0.5mg to 1mg IV bolus
- **Repeat dosing:** 1mg every 3-5 minutes (not 0.5mg)
- **Maximum total:** 3mg (unchanged)

**Dopamine Infusion Updates:**
- **Dosing range:** 5-20 mcg/kg/min (updated from 2-20 mcg/kg/min)
- **Starting dose:** 5 mcg/kg/min for chronotropic effect
- **Maximum:** 20 mcg/kg/min with careful monitoring

### **Advanced Monitoring Capabilities:**
- **Continuous telemetry:** Real-time rhythm analysis
- **POCUS integration:** IVC assessment for volume status
- **Arterial line placement:** For unstable patients requiring vasopressors
- **Central venous access:** When transvenous pacing anticipated

### **Cardiology Integration:**
**24/7 Availability:**
- **Interventional cardiology:** For emergency pacemaker placement
- **Electrophysiology:** Specialized arrhythmia management
- **Transfer Center:** 856-886-5111 for consultation and transfer

**Pacemaker Program:**
- **Temporary pacing:** Available in ED and ICU
- **Permanent device placement:** Within 24-48 hours for appropriate candidates
- **Device clinic:** Follow-up and optimization

### **H's and T's Assessment for Bradycardia:**
**Hypoxia:** Airway management, supplemental oxygen
**Hydrogen ions (Acidosis):** ABG analysis, bicarbonate if severe
**Hypovolemia:** Fluid resuscitation, bleeding assessment
**Hypo/Hyperkalemia:** Electrolyte correction protocols
**Hypothermia:** Rewarming strategies
**Toxins:** Antidote administration (calcium, glucagon)
**Tamponade:** Echocardiogram, pericardiocentesis
**Tension pneumothorax:** Chest decompression
**Thrombosis:** PE/MI evaluation and treatment
**Tablets (drugs):** Beta-blockers, calcium channel blockers, digoxin

### **Special Population Considerations:**
**Elderly Patients:**
- Higher baseline bradycardia tolerance
- Medication-induced causes common
- Careful sedation dosing for pacing

**Post-Cardiac Surgery:**
- Temporary epicardial wires available
- Electrolyte management critical
- Early EP consultation

**Heart Transplant Recipients:**
- Atropine ineffective (denervated heart)
- Direct chronotropic agents preferred
- Specialized cardiology consultation

### **Quality Improvement Metrics:**
- **Recognition time:** <5 minutes from RRT activation
- **Atropine administration:** <15 minutes from assessment
- **Pacing setup:** <30 minutes for high-risk blocks
- **Cardiology consultation:** <60 minutes for complex cases

## REFERENCE GUIDELINES
- **2020 AHA Guidelines for CPR and Emergency Cardiovascular Care**
- **2018 AHA/ACC/HRS Guideline on Bradycardia and Cardiac Conduction Delay**
- **2025 ACLS Algorithm Updates**
- **Virtua Health System Bradycardia Protocol v2025**

**This protocol reflects current evidence-based ACLS guidelines with 2025 updates, optimized for rapid recognition and appropriate intervention of symptomatic bradycardia in the Virtua Voorhees RRT setting.**
